These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23449351)

  • 1. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
    Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
    Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
    Spencer SK; Pommier AJ; Morgan SR; Barry ST; Robertson JD; Hoff PM; Jürgensmeier JM
    Br J Cancer; 2013 Nov; 109(11):2765-73. PubMed ID: 24149180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
    Cunningham D; Wong RP; D'Haens G; Douillard JY; Robertson J; Stone AM; Van Cutsem E;
    Br J Cancer; 2013 Feb; 108(3):493-502. PubMed ID: 23299530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
    Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
    Van Cutsem E; Paccard C; Chiron M; Tabernero J
    Clin Cancer Res; 2020 Feb; 26(3):717-725. PubMed ID: 31727675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
    Pommier AJ; Shaw R; Spencer SK; Morgan SR; Hoff PM; Robertson JD; Barry ST; Jürgensmeier JM
    Br J Cancer; 2014 Oct; 111(8):1590-604. PubMed ID: 25121956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
    Zhou C; Taylor S; Tugwood J; Simpson K; Jayson GC; Symonds P; Paul J; Davidson S; Carty K; McCartney E; Rai D; Dive C; West C
    Br J Clin Pharmacol; 2019 Aug; 85(8):1781-1789. PubMed ID: 30980733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
    Kato T; Muro K; Yamaguchi K; Bando H; Hazama S; Amagai K; Baba H; Denda T; Shi X; Fukase K; Skamoto J; Mishima H
    Ann Oncol; 2012 Apr; 23(4):933-41. PubMed ID: 21828378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
    Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
    J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
    Tabernero J; Hozak RR; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Prausová J; Muro K; Siegel RW; Konrad RJ; Ouyang H; Melemed SA; Ferry D; Nasroulah F; Van Cutsem E
    Ann Oncol; 2018 Mar; 29(3):602-609. PubMed ID: 29228087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
    Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
    J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.